

Cumulative Index 2004

Volume 25

March	IATROGENIC LUNG DISEASE, pages 1–236
June	SEX, GENDER, AND RESPIRATORY HEALTH AND DISEASE, pages 237–408
September	INTERSTITIAL LUNG DISEASE: NONIDIOPATHIC INTERSTITIAL PNEUMONIA, pages 409–620
December	INTERSTITIAL LUNG DISEASE: IDIOPATHIC INTERSTITIAL PNEUMONIA, pages 621–810

Note: Page numbers of article titles are in **boldface** type.

A

ACE inhibitors. See *Angiotensin-converting enzyme (ACE) inhibitors*.

Acebutolol

BOOP due to, 87

Acetazolamide

pulmonary edema due to, 94

Acute diffuse alveolar hemorrhage

acute lung injury and, 666–668

Acute interstitial pneumonia (AIP), **739–747**

clinical course of, 742–743

defined, 739–740

differential diagnosis of, 743–744

epidemiology of, 742

future directions in, 745

historical perspective of, 739–740

long-term prognosis of, 745

pathogenesis of, 741–742

pathology of, 740–741

survival following, 744

treatment of, 744

Acute lung injury (ALI)

pattern of, 660–668

transfusion-related

pulmonary injury due to, **101–107**. See also

Transfusion-related acute lung injury (TRALI).

Acute respiratory distress syndrome (ARDS)

drug-induced, 98

pregnancy and, 305

Acyclovir

pleural disease due to, 144

α-Adrenergic antagonists

bronchospasm–asthma due to, 109–110

Adult respiratory distress syndrome (ARDS)

acute lung injury and, 662

Aerobic capacity

in women

blood volume and hemoglobin effects on, 249

cardiac output and, 249–250

exercise performance effects of, 249–251

ventilation and, 250–251

Age

as factor in lymphangioleiomyomatosis, 355

as factor in NSIP, 709

AIP. See *Acute interstitial pneumonia (AIP)*.

Air embolism

pregnancy and, 304–305

Airspace filling

in interstitial lung diseases, 682–686

Airway diseases

drug-induced, **109–118**

BOOP, 115

bronchiolitis obliterans, 115

bronchoconstriction, 110–112

bronchospasm, 112–113

bronchospasm–asthma, 109–113

cough, 113–115

- Airway function
 in women, 321-330
 bronchial hyperresponsiveness and, 321-324
 cough and, 324
 vocal cord dysfunction and, 324-328
- Alemtuzumab
 pulmonary infection due to, 182
- ALI. See *Acute lung injury (ALI)*.
- Alkaloid(s)
 vinca
 ARDS due to, 98
- Alkylating agents
 lung diseases due to, 54-55
- All-trans-retinoic acid (ATRA), 57
 diffuse alveolar hemorrhage due to, 133
- Alveolar damage
 diffuse
 pulmonary edema with/without
 drug-induced, 17-18
- Alveolar hemorrhage
 diffuse
 after bone marrow transplantation, 189
- Alveolar microlithiasis
 pulmonary, 429
- Alveolar ventilation
 neuromuscular determinants of, 153
- American Thoracic Society/European
 Respiratory Society
 histologic classification of idiopathic pulmonary
 fibrosis, 622-623
- Amiodarone
 ARDS due to, 98
 BOOP due to, 87
 in interstitial lung disease, 680-681
 pharmacokinetics of, 63-64
 pleural disease due to, 140
 pleural effusion due to, 68-69
 pleural thickening due to, 69
 pulmonary toxicity associated with, 63-72
 BAL for, 67
 clinical imaging patterns of, 64-66
 early detection of, 69
 epidemiology of, 64
 histopathologic evaluation for, 67
 outcome of, 68
 patient work-up for, 67-68
 prevention of, 69
 pulmonary function testing for, 66-67
 risk factors for, 64
- Amlodipine
 pulmonary edema due to, 93-94
- Amniotic fluid embolism
 pregnancy and, 301-302
- Amphotericin B
 BOOP due to, 86
- Analgesic(s)
 acute lung injury and, 663
 pulmonary edema due to, 95-96
- Anesthesia/anesthetics
 in thoracic endometriosis management, 316
 neuromuscular respiratory system dysfunction due
 to, 155
- Angiogenesis
 in idiopathic pulmonary fibrosis, 752-753
- Angiography
 in thoracic endometriosis, 314
- Angiostasis
 in idiopathic pulmonary fibrosis, 752-753
- Angiotensin-converting enzyme (ACE) inhibitors
 cough due to, 113-115
- Anorectic(s)
 next generation of, 120
- Anorectic pulmonary hypertension
 PPH and
 comparison of, 121-122
- Anticancer agents
 BOOP due to, 86
- Anticoagulant(s)
 diffuse alveolar hemorrhage due to, 134
- Antidepressant(s)
 tricyclic
 pulmonary edema due to, 95
- Antigen(s)
 hypersensitivity pneumonitis due to, 531
- Antiglomerular basement membrane disease
 acute lung injury and, 666
- Anti-inflammatory drugs
 BOOP due to, 87-88
 nonsteroidal (NSAIDs)
 infiltrative lung diseases due to, 47
- Antimetabolite(s)
 lung diseases due to, 55-57
- Antimicrobial drugs
 BOOP due to, 85-86

- Antineoplastic agents
ARDS due to, 98
pulmonary edema due to, 92-93
- Antioxidant(s)
for pulmonary fibrosis, 764-765
- ARDS. See *Acute respiratory distress syndrome (ARDS)*.
- Arthritis
rheumatoid, 552-553
acute lung injury and, 665
pulmonary fibrosis in, 668-669
- Asbestosis, 500-501
in female workers, 274-275
- Aspergillus* spp.
pulmonary infection due to
corticosteroids and, 179
- Aspiration pneumonitis
pregnancy and, 306
- Aspirin
infiltrative lung diseases due to, 46-47
pulmonary edema due to, 95-96
- Asthma
occupational
in female workers, 276
pregnancy and, 307-308
- ATRA. See *All-trans-retinoic acid (ATRA)*.
- Autoimmune diseases
gender issues in, 375-376
- Azathioprine
lung diseases due to, 55-56
- B**
- Bacterial infections
after bone marrow transplantation, 190-191
- BAL. See *Bronchoalveolar lavage (BAL)*.
- Baseline demographic variables
in pulmonary fibrosis management, 761
- Benign metastasizing leiomyoma (BML), 343-354
clinical characteristics of, 345
defined, 343
described, 343
diagnosis of, 345-352
differential diagnosis of, 348-352
growth patterns of
unusual, 353-354
hormonal features of, 357-358
lymphangioleiomyomatosis and, 354-355
multiple growth, 345
pathogenesis of, 343-345
pathology of, 346-348
prevalence of, 343
radiologic findings in, 346
treatment of, 352-353
- Berylliosis
nodules in, 688-689
- Bioactivation
in drug-induced lung cell injury, 1-5
- Bioaerosol-associated atypical
mycobacterial infection
interstitial mononuclear cells in, 679
- Biological markers
in thoracic endometriosis, 314
- Bird-related hypersensitivity pneumonitis,
531-532
- Bleomycin
BOOP due to, 86
lung diseases due to, 53-54
pleural disease due to, 141
pulmonary fibrosis and, 670
- α -Blockers
pleural disease due to, 140
- Blood volume
aerobic capacity effects of
in women, 249
- BML. See *Benign metastasizing leiomyoma (BML)*.
- Bone marrow transplantation
pulmonary complications in, 187-199
bacterial infections, 190-191
bronchiolitis obliterans, 193
CMV pneumonitis, 191-192
cryptogenic organizing pneumonia, 194
delayed pulmonary toxicity syndrome,
193-194
diagnosis of, 194-195
diffuse alveolar hemorrhage, 189
engraftment syndrome, 189-190
fungal infections, 190-191
herpes simplex pneumonitis, 191
idiopathic pneumonia syndrome, 192-193
in posttransplant phase 1, 189-191
in posttransplant phase 2, 191-193
in posttransplant phase after bone marrow
transplantation, 193-194

- long-term outcome of, 195-197
 - management of
 - algorithmic approach to, 197
 - miscellaneous, 194
 - Pneumocystis carinii* pneumonia, 192
 - pulmonary edema, 189
 - temporal patterns of, 188
 - viral infections, 190-191
 - sources of, 187, 188
- BOOP.** See *Bronchiolitis obliterans organizing pneumonia (BOOP).*
- Breast cancer, 382-384**
- histologic variants of, 382-383
 - metastatic
 - pleural effusion due to, 383-384
 - pulmonary lymphangitis due to, 384
 - tumor emboli due to, 384
 - metastatic patterns of, 383
 - parenchymal metastasis in, 383
 - prevalence of, 382
 - thoracic manifestations of, 382-384
- Breathing**
- sleep-disordered
 - pregnancy and, 262
- Bromocriptine**
- pleural disease due to, 141
- Bronchial hyperresponsiveness**
- in women, 321-324
 - air function effects of, 321-324
 - morbidity associated with, 322
 - mortality associated with, 322
 - obesity and, 323
 - prevalence of, 321-322
 - psychologic factors and, 323-324
 - tobacco use and, 323
 - treatment of
 - implications of, 324
 - vs. men, 322-323
- Bronchiectasis, 361-372**
- clinical features of, 361
 - epidemiology of, 361-362
 - gender issues related to, 363-367
 - speculative hypotheses of, 369
 - infection and, 368-369
 - inflammation and, 368-369
 - noncystic fibrosis
 - mycobacterial infection and, 364-365
 - pathogenesis of, 362-363
 - sex as factor in, 367-369
- Bronchiolitis**
- nodular
 - nodules in, 689
 - respiratory. See *Respiratory bronchiolitis.*
- Bronchiolitis obliterans**
- after bone marrow transplantation, 193
 - drug-induced, 16, 115
- Bronchiolitis obliterans organizing pneumonia (BOOP)**
- drug-induced, 16, 85-90, 115
 - acetyltololol in, 87
 - amiodarone in, 87
 - amphotericin B in, 86
 - anticancer agents in, 86
 - anti-inflammatory agents in, 87-88
 - antimicrobial drugs in, 85-86
 - bleomycin in, 86
 - carbamazepine in, 88
 - cardiovascular agents in, 87
 - cephalosporin in, 86
 - doxorubicin in, 86
 - gold in, 87
 - interferons in, 88
 - minocycline in, 85
 - nitrofurantoin in, 85-86
 - phenytoin in, 88
 - sulfasalazine in, 87-88
 - ticlopidine in, 88
 - L-tryptophan in, 88-89
 - drug-induced infiltrative lung disease and, 507-508
- Bronchoalveolar lavage (BAL)**
- bronchoscopy with
 - for pulmonary complications of bone marrow transplantation, 194-195
 - for amiodarone pulmonary toxicity, 67
 - in COP, 731-732
 - in drug-induced lung disease, 25-34. See also *Lung disease, drug-induced, BAL in.*
 - in drug-induced pneumonitis, 28-31
 - in hypersensitivity pneumonitis, 536-537
 - in interstitial lung disease, 637-648. See also *Interstitial lung disease, BAL in.*
 - in respiratory bronchiolitis-associated desquamative interstitial pneumonia, 722
 - in respiratory bronchiolitis-associated interstitial lung disease, 722
- Bronchoconstriction**
- NSAID-induced
 - aspirin and, 110-112

Bronchoscopy

- in diffuse alveolar hemorrhage, 586
- in idiopathic pulmonary fibrosis, 628
- in PLCH, 566-567
- in thoracic endometriosis, 313-314
- with BAL
 - for pulmonary complications of bone marrow transplantation, 194-195

Bronchospasm

- drug-induced
 - inhalational agents in, 112
 - vinca alkaloids in, 113

Bronchospasm-asthma

- drug-induced, 109-113
- α-adrenergic antagonists in, 109-110

Bush tea drinkers

- pulmonary hypertension in, 124

Busulfan

- lung diseases due to, 54

C**Calcium channel blockers**

- pulmonary edema due to, 93-94

Cancer

- breast, 382-384. See also *Breast cancer*.
- cervical
 - thoracic manifestations of, 385-387. See also *Cervical cancer*.
- esophageal
 - therapy-induced, 219
- lung. See *Lung cancer*.
 - radiation therapy for
 - lung damage after
 - manifestations of, 168-170
 - therapy-induced
 - studies of, 217-219
- ovarian
 - thoracic manifestations of, 384-385. See also *Ovarian cancer*.
- thoracic
 - therapy-induced, 215-224. See also *Thoracic malignancies, therapy-induced*.
- uterine
 - thoracic manifestations of, 385-387. See also *Uterine cancer*.

Carbamazepine

- BOOP due to, 88

Cardiac output

- aerobic capacity effects of
 - in women, 249-250

Cardiomyopathy

- peripartum, 303

Cardiovascular agents

- BOOP due to, 87
- pleural disease due to, 139-140
- pulmonary edema due to, 93-94

Cephalosporin

- BOOP due to, 86

Cervical cancer

- endobronchial disease due to, 386-387
- lymphangitic carcinomatosis due to, 386-387
- parenchymal disease due to, 386
- pleural disease due to, 386, 387
- prevalence of, 385-386
- thoracic manifestations of, 385-387

Chemical-induced hypersensitivity

- pneumonitis, 533

Chemotherapeutic agents

- acute lung injury and, 663
- diffuse alveolar hemorrhage due to, 134
- emerging agents, 57-58
- novel agents, 57-58
- pleural disease due to, 141-143

Chemotherapy

- lung diseases due to, 51-62. See also *Lung diseases, chemotherapy-induced*.

Chest imaging

- in iatrogenic respiratory disease, 15-24

Chest radiography

- in hypersensitivity pneumonitis, 535
- in interstitial lung disease, 414-415

Children

- lung development in, 239-240
- smoking effects on, 240-241

Chlorambucil

- lung diseases due to, 55

Chlorothiazide/hydrochlorothiazide

- pulmonary edema due to, 94-95

Chronic interstitial pneumonia

- drug-induced lung disease and, 38-39

Chronic obstructive pulmonary disease (COPD),

- 331-341
 - diagnosis of
 - gender bias in, 335-337
 - epidemiology of, 331-332
 - in women

- clinical course of, 338-339
 - epidemiology of, 333-335
 - predisposition for factors affecting, 337-338
- Cigarette smoking
- hypersensitivity pneumonitis due to, 534
 - interstitial lung disease related to, 695-698
 - women and, 332-333
- Clozapine
- pleural disease due to, 144-145
- Clubbing
- as factor in NSIP, 709
- CMV. See *Cytomegalovirus (CMV)*.
- Cocaine
- diffuse alveolar hemorrhage due to, 134
 - pulmonary edema due to, 97
 - pulmonary effects of, 204-205, 207-210
 - pulmonary hypertension due to, 123-124
- Collagen vascular diseases, 462-463
- acute pulmonary manifestations of, 664-665
 - diffuse alveolar hemorrhage due to, 588
 - interstitial lung disease with lung transplantation for, 776-777
- Computed tomography (CT)
- high-resolution
 - in hypersensitivity pneumonitis, 535
 - in interstitial lung disease, 457-458
- Congenital pulmonary alveolar proteinosis
- mutation of CSF2RB gene and, 426-427
- Connective tissue disease
- interstitial lung disease with, **549-559**. See also *Interstitial lung disease, in patient with connective tissue disease*.
 - mixed, 555-556
 - undifferentiated, 556
- Continuous positive airway pressure (CPAP)
- for obstructive sleep apnea, 263
- Contraceptive(s)
- oral
 - venous thromboembolism due to, 283-285
- Contrast agents
- pulmonary edema due to, 97
- COP. See *Cryptogenic organizing pneumonia (COP)*.
- COPD. See *Chronic obstructive pulmonary disease (COPD)*.
- Coronary artery disease
- lung transplantation for interstitial lung disease and, 778-779
- Corticosteroid(s)
- Aspergillus* spp. disorders due to, 179
 - Mycobacterium tuberculosis* disorders due to, 179-180
 - neuromuscular respiratory system dysfunction due to, 159
 - Pneumocystis carinii* pneumonia due to, 178-179
 - pulmonary infection due to, 177-180
- Cough
- drug-induced, 113-115
 - in women
 - air function effects of, 324
- CPAP. See *Continuous positive airway pressure (CPAP)*.
- CREST syndrome
- progressive systemic sclerosis and, 463
- Cryptogenic organizing pneumonia, 556
- after bone marrow transplantation, 194
- Cryptogenic organizing pneumonia (COP), **727-738**
- BAL in, 731-732
 - causes of, 728-729
 - clinical manifestations of, 729-730
 - defined, 727
 - diagnostic criteria for, 727-729, 734
 - clinical-radiologic-pathologic, 727-728
 - etiologic, 728
 - pathologic, 727
 - imaging of, 653, 730-732
 - laboratory findings in, 731-732
 - lung function tests in, 732
 - progressive, 733-734
 - severe, 733-734
 - terminology associated with, 727
 - treatment of, 732-733
- CSF2RB gene
- mutation of
 - congenital pulmonary alveolar proteinosis and, 426-427
- CT. See *Computed tomography (CT)*.
- Cyclophosphamide
- for systemic sclerosis, 554
 - lung diseases due to, 54-55
 - pleural disease due to, 142-143
- Cyclosporin
- pulmonary infection due to, 180

- Cystic fibrosis
 - gender issues related to, 363-367
 - Pseudomonas aeruginosa* infection and sex-related effects of, 367-368
- Cytarabine
 - ARDS due to, 98
- Cytarabine arabinoside
 - pulmonary edema due to, 92-93
- Cytokine(s)
 - profibrotic Th2
 - in idiopathic pulmonary fibrosis, 753
- Cytomegalovirus (CMV) pneumonitis
 - after bone marrow transplantation, 191-192
- Cytosine arabinoside
 - lung diseases due to, 56

D

DAH. See *Diffuse alveolar hemorrhage (DAH)*.

- Dantrolene
 - pleural fluid eosinophilia due to, 144
- Deep venous thrombosis
 - pulmonary embolism and relationship between, 281
- Delayed pulmonary toxicity syndrome
 - after bone marrow transplantation, 193-194
- Dermatomyositis/polymyositis
 - acute lung injury and, 665
 - pulmonary fibrosis in, 670
- Desquamative interstitial pneumonia
 - defined, 718
 - lung transplantation for, 777
 - respiratory bronchiolitis-associated, **717-726**
 - clinical features of, 722-723
 - clinical issues with, 723
 - diagnostic evaluation of, 720-722
 - histopathology of, 718-719
 - prognosis of, 723
 - smoking and, 719-720
 - treatment of, 722-723
- Desquamative interstitial pneumonitis
 - imaging of, 653-654
- Dexfenfluramine
 - pulmonary hypertension due to, 122
- Diffuse alveolar damage
 - acute lung injury and, 662
 - drug-induced lung disease and, 39

- idiopathic
 - acute lung injury and, 668
 - pulmonary edema with/without drug-induced, 17-18

Diffuse alveolar hemorrhage (DAH), **583-592**

- acute
 - acute lung injury and, 666-668
 - after bone marrow transplantation, 189
 - causes of, 583-584, 586-587
 - clinical presentation of, 584-585
 - collagen vascular diseases and, 588
 - defined, 583
 - described, 583
 - diagnosis of
 - approach to, 585-586
 - differential diagnosis of, 585
 - drug-induced, **129-137**, 589
 - anticoagulants in, 134
 - ATRA in, 133
 - chemotherapeutic agents in, 134
 - clinical picture of, 132
 - cocaine in, 134
 - histopathology of, 129-132
 - leukotriene antagonists in, 134
 - mitomycin in, 133-134
 - propylthiouracil in, 132-133
 - thrombolytic agents in, 134
 - Goodpasture's syndrome and, 588
 - histopathology of, 585
 - idiopathic pulmonary hemosiderosis and, 588-589
 - isolated pulmonary capillaritis and, 589
 - microscopic polyangiitis and, 587-588
 - Wegener's granulomatosis and, 587
- Diffuse panbronchiolitis
 - nodules in, 689-690
- Docetaxel
 - lung diseases due to, 58
- Doxorubicin
 - BOOP due to, 86
- Drug(s)
 - acute lung injury and, 663
 - BOOP due to, **85-90**. See also *Bronchiolitis obliterans organizing pneumonia (BOOP)*, *drug-induced*.
 - diffuse alveolar hemorrhage due to, **129-137**, 587. See also *Diffuse alveolar hemorrhage (DAH)*, *drug-induced*.
 - eosinophilic lung disease due to, **73-84**. See also *Eosinophilic lung disease*, *drug-induced*.
 - illicit use of. See *specific drug and illicit drug use*.

- infiltrative lung disease due to, 479-519. See also *Infiltrative lung disease, drug-induced*.
- lung cell injury due to
- causes of, 6-7
 - mechanisms in, 1-6
 - bioactivation, 1-5
 - direct cytotoxicity, 5-6
 - models of, 10
 - risk factors for, 7-10
 - genetic predisposition, 9
 - metabolic idiosyncrasy, 8-9
 - susceptibility to healing of inflammation or fibrogenesis, 9-10
- lung diseases due to, 15-19. See also *Lung diseases, drug-induced*.
- pleural disease due to, 139-151. See also *Pleural disease, drug-induced*.
- pulmonary edema due to, 91-97. See also *Pulmonary edema, drug-induced*.
- pulmonary hypertension due to, 119-127. See also *Pulmonary hypertension, drug therapy and*.
- respiration during sleep effects of, 156
- sarcoidosis due to, 513-514
- Drug use
- illicit. See *Illicit drug use*.
 - injection
 - pulmonary effects of, 201
- Dust
- fibrous
 - occupational interstitial lung disease due to, 470-472
 - nonfibrous
 - occupational interstitial lung disease due to, 472-473
- Dynamic clinical variables
- in pulmonary fibrosis management, 761-762
- Dyskinesia
- neuromuscular respiratory system dysfunction due to, 156
- Dyspnea
- exertional
 - vocal cord dysfunction in women and, 325
- Dyspnea score
- in lung damage assessment after radiation therapy for lung cancer, 168-169
- E**
- Ecstasy
- pulmonary hypertension due to, 124
- Edema
- pulmonary
 - drug-induced, 91-97. See also *Pulmonary edema, drug-induced*.
 - drug-induced lung disease and, 40
 - pregnancy and, 303
 - tocolytic-induced
 - pregnancy and, 302
- Effusion(s)
- pleural
 - breast cancer and, 383-384
- Eicosanoid(s)
- for pulmonary fibrosis, 766
- Embolism
- air
 - pregnancy and, 304-305
 - amniotic fluid
 - pregnancy and, 301-302
 - pulmonary
 - deep venous thrombosis and relationship between, 281
- Embolization
- iatrogenic
 - to pulmonary arteries, 22
- Embolus(i)
- tumor
 - breast cancer and, 384
- Endobronchial disease
- cervical cancer and, 366-367
 - ovarian cancer and, 385
 - uterine cancer and, 386-387
- Endobronchial obstruction, 382
- Endometriosis
- described, 311
 - history of, 311
 - thoracic, 311-319
 - clinical manifestations of, 311-312
 - demographics of, 312-313
 - diagnosis of, 313-314
 - epidemiology of, 312-313
 - pathogenesis of, 314-315
 - pathologic findings in, 314
 - treatment of, 315-316
 - anesthetic concerns in, 316
- Endothelin
- for pulmonary fibrosis, 765
- Engraftment syndrome
- after bone marrow transplantation, 189-190

- Eosinophil(s)
 - biology of, 73
- Eosinophilia
 - pleural fluid
 - drug(s) causing, 143-144
 - drug-induced pleural disease and, 143-144
 - pulmonary
 - drug-induced lung disease and, 40
- Eosinophilic lung disease
 - acute
 - acute lung injury and, 663-664
 - diagnosis of, 74-75
 - differential diagnosis of, 75-76
 - drug-induced, 73-84
 - causes of, 76-78
 - clinical approach to, 79-80
 - clinical patterns of, 78-79
- Eosinophilic myalgia syndrome, 124
- Eosinophilic pneumonia
 - airspace filling in, 684-685
- Epinephrine
 - pulmonary edema due to, 94
- Epithelial cell apoptosis
 - in idiopathic pulmonary fibrosis, 751-752
- Epoprostenol
 - pulmonary edema due to, 94
- Ergoline drugs
 - pleural disease due to, 141
- Ergonovine
 - pulmonary edema due to, 96
- Esophageal cancer
 - therapy-induced, 219
- Ethchlorvynol
 - pulmonary edema due to, 95
- Etoposide
 - lung diseases due to, 58
- Exercise performance
 - in women
 - aerobic capacity and, 249-251. See also *Aerobic capacity, in women.*
 - body composition effects on, 248-249
 - body size effects on, 248-249
 - implications for, 253
 - physiologic considerations in, 247-255
 - substrate metabolism and, 251
 - thermoregulation effects on, 251-253
- Exertional dyspnea
 - vocal cord dysfunction in women and, 325

F

- Familial hypocalciuric hypocalcemia
 - pulmonary fibrosis-related, 424
- Familial idiopathic pulmonary fibrosis, 428-429
- Familial interstitial lung disease
 - reduced surfactant protein C expression associated with, 427-428
 - surfactant protein C mutations and, 427-428
- Farmer's lung, 532
- Fatal surfactant deficiency, 426
- Female reproductive hormones, 247-248
- Fenfluramine
 - in lung
 - accumulation of, 123
 - pulmonary hypertension due to, 122
- Fetus
 - lung development in, 237-239
 - smoking effects on, 240-241
- Fibroblast phenotypes
 - altered
 - in idiopathic pulmonary fibrosis, 753-754
- Fibrosis(es)
 - cystic. See *Cystic fibrosis.*
 - pulmonary. See *Pulmonary fibrosis.*
 - idiopathic
 - management of, 621-634. See also *Idiopathic pulmonary fibrosis, management of.*
 - paradox of, 755
- Fibrous dust
 - occupational interstitial lung disease due to, 470-472
- Fludarabine
 - lung diseases due to, 56
- Follicular bronchiolitis
 - nodules in, 689
- Fungal infections
 - after bone marrow transplantation, 190-191

G

- GCSF. See *Granulocyte colony-stimulating factor (GCSF).*
- Gefitinib, 57-58
- Gemcitabine
 - lung diseases due to, 56
 - pulmonary edema due to, 93

Gender

- as factor in bronchiectasis, 363-367. See also *Bronchiectasis*.
- as factor in COPD, 335-337
- as factor in cystic fibrosis, 366-367
- as factor in NSIP, 709
- as factor in occupational lung disease, 269-273
- as factor in pulmonary vascular disease, 373-377. See also *Pulmonary vascular disease, gender issues in*.
- as factor in venous thromboembolism, 281-297
- as risk factor for lung cancer, 391-400. See also *Lung cancer, gender and*.
- defined, 269
- in lung development
 - clinical significance of, 237-245. See also *Lung development, gender differences in*.

Gender reproductive hormones, 247-248

Genetic(s)

- hypersensitivity pneumonitis and, 540-541
- of inherited interstitial lung disease, 425-429

Genetic predisposition

- drug-induced lung cell injury due to, 9

Gliclazide

- pleural fluid eosinophilia due to, 144

GM-CSF. See *Granulocyte-macrophage colony-stimulating factor (GM-CSF)*.

Gold

- BOOP due to, 87

Gold salts

- infiltrative lung diseases due to, 48

Goodpasture's syndrome

- acute lung injury and, 666
- diffuse alveolar hemorrhage due to, 588

Graft versus host disease

- transplant-related, 20

Granulocyte colony-stimulating factor (GCSF)

- lung diseases due to, 59
- pleural disease due to, 145

Granulocyte-macrophage colony-stimulating factor (GM-CSF)

- antibodies to
 - diagnostic tests related to, 601-603
 - for pulmonary alveolar proteinosis, 605-606
- in alveolar macrophage development and function, 603-605
- in pulmonary alveolar proteinosis, 596

lack of

- pulmonary pathology in persons with experimental approaches to, 599-601
- lung diseases due to, 59

Granuloma(s)

- nodular
 - in interstitial lung disease, 686-690

Granulomatosis

- Wegener's
 - diffuse alveolar hemorrhage due to, 587

Granulomatous inflammation

- drug-induced lung disease and, 41-42

Growth factor

- production and function of
 - in idiopathic pulmonary fibrosis, 753

H**Hemoglobin**

- aerobic capacity effects of
 - in women, 249

Hemorrhage

- alveolar
 - diffuse
 - after bone marrow transplantation, 189
 - diffuse alveolar. See *Diffuse alveolar hemorrhage*.
 - acute
 - acute lung injury and, 666-668
 - pulmonary
 - drug-induced, 18-19
 - drug-induced lung disease and, 40-41

Hereditary surfactant protein B deficiency, 425-426

Hermansky-Pudlak syndrome

- pulmonary fibrosis in, 670-672
- pulmonary fibrosis-related, 424

Heroin

- pulmonary edema due to, 97
- pulmonary effects of, 201-204

Herpes simplex pneumonitis

- after bone marrow transplantation, 191

Hiccups

- neuromuscular respiratory system dysfunction due to, 156

Histiocytosis

- Langerhans' cell, 462
- lung transplantation for, 777

HIV. See *Human immunodeficiency virus (HIV)*.

- Hormonal therapy**
 venous thromboembolism due to, 283-288
 HRT, 286-287
 oral contraceptives, 283-285
 SERMs, 287-288
- Hormone(s)**
 reproductive
 female, 247-248
- Hormone replacement therapy (HRT)**
 venous thromboembolism due to, 286-287
- HRT.** See *Hormone replacement therapy (HRT).*
- Human immunodeficiency virus (HIV)**
 pulmonary complications due to
 pregnancy-related, 307
- Hydralazine**
 lupus pleuritis due to, 148
- Hydrochlorothiazide**
 infiltrative lung diseases due to, 48-49
- Hypercalcemia**
 familial hypocalciuric
 pulmonary fibrosis-related, 424
- Hyperresponsiveness**
 bronchial
 in women, 321-324. See also *Bronchial hyperresponsiveness, in women.*
- Hypersensitivity lung disease**
 drug-induced, 16
- Hypersensitivity pneumonitis, 463-464, 531-547**
 acute, 533
 antigens and, 531
 bird-related, 531-532
 causes of, 532
 chemical-induced, 533
 chronic, 533-534
 cigarette smoking and, 534
 clinical presentation of, 533
 CT in
 high-resolution, 535
 described, 531
 diagnosis of
 BAL in, 536-537
 criteria for, 539
 imaging in, 535-536
 laboratory tests in, 534-535
 differential diagnosis of, 538-539
 disturbed lung hypersensitivity in, 541-542
 emergent types of, 531-534
 factors contributing to, 540-542
 farmer's lung, 532
 fibrosis connection in, 542
 genetics and, 540-541
 histopathologic features of, 537-538
 interstitial mononuclear cells in, 677-679
 laboratory abnormalities in, 534-535
 management of, 539-540
 mycobacterial-induced, 532-533
 outcome of, 539-540
 pathogenic mechanisms of, 540
 physiologic features of, 535-536
 prognosis of, 540
 subacute, 533
 survival rates in, 540
 viral connection in, 541
- Hypertension**
 pulmonary, 554. See *Pulmonary hypertension.*
-
- I**
- Iatrogenic embolization**
 to pulmonary arteries, 22
- Iatrogenic infiltrative lung disease, 479-519**
- Iatrogenic respiratory disease.** See also *Lung diseases.*
 chest imaging in, 15-24
- Idiopathic diffuse alveolar damage**
 acute lung injury and, 668
- Idiopathic pneumonia syndrome**
 after bone marrow transplantation, 192-193
- Idiopathic pulmonary fibrosis (IPF)**
 American Thoracic Society/European Respiratory Society histologic classification of, 622-623
 as abnormality in host defense, 754-755
 chest imaging of, 625
 clinical evaluation of, 625-626
 current understanding of, 622-625
 diagnostic evaluation of, 625-630
 bronchoscopy in, 628
 laboratory tests in, 626
 pulmonary function tests in, 626
 radiographic studies in, 626-628
 surgical lung biopsy in, 628-630
 epidemiology of, 622
 familial, 428-429
 genetic polymorphisms and
 relationship between, 429-430
 historical perspective on, 621-622
 lung transplantation for, 775
 management of, 621-634

- approach to, 631-632
 - new therapies in, 631
 - traditional therapies in, 630
 - natural history of, 624
 - paradox of, 755
 - pathogenesis of, **749-758**
 - altered fibroblast phenotypes in, 753-754
 - angiogenesis in, 752-753
 - angiostasis in, 752-753
 - epithelial cell apoptosis in, 751-752
 - evolving paradigms in, 751
 - growth factor production and function in, 753
 - imbalance of matrix production and degradation in, 753
 - myofibroblast recruitment and maintenance in, 754
 - profibrotic Th2 cytokines in, 753
 - proliferation in, 751-752
 - pathophysiology of, 623-624
 - resting and exercise physiology in, 439-441
- Idiopathic pulmonary hemosiderosis**
acute lung injury and, 667-668
diffuse alveolar hemorrhage due to, 588-589
- Idiopathic pulmonary hypertension.** See *Primary pulmonary hypertension (PPH)*.
- IgE-mediated mechanism**
bronchospasm due to, 112-113
- Illicit drug use**
pulmonary effects of, **201-214**
 - cocaine, 204-205, 207-210
 - heroin, 201-204
 - inhalation drugs, 205
 - marijuana, 205-207
- Imaging studies**
in thoracic endometriosis, 313
- Immune modulatory agents**
lung diseases due to, 58-59
- Immunoglobulin(s)**
IgE
 - bronchospasm due to, 112-113**intravenous**
 - pleural disease due to, 147**lymphocyte**
 - ARDS due to, 98
- Immunosuppressive agents**
ARDS due to, 98
for pulmonary fibrosis
 - limitations of, 762-763
pulmonary edema due to, 92-93
- Infection(s).** See also specific types, e.g., *Bacterial infections*.
acute lung injury and, 663
bronchiectasis and, 368-369
transplant-related, 19-20
- Infiltrative lung disease**
drug-induced, **479-519**
 - amiodarone pneumonitis-amiodarone pulmonary toxicity, 508-509
 - clinical scenarios relevant to pulmonologist, 459-467
 - described, 479-480
 - diagnostic criteria for, 481
 - organizing pneumonia, 469-472
 - pleuropulmonary reactions to, 475
 - subacute/chronic, 505-507**iatrogenic, 479-519**
irradiation to chest and, 515-516
nontoxic agents and, **45-50**. See also *Lung diseases, infiltrative, nontoxic agents and*.
radiation-induced vascular injury and, 512-513
- Inflammation**
bronchiectasis and, 368-369
granulomatous
drug-induced lung disease and, 41-42
- Infliximab**
ARDS due to, 98
- Inhalational agents**
bronchospasm due to, 112
pulmonary effects of, 205
- Inherited interstitial lung disease, 421-433.** See also *Interstitial lung disease, inherited*.
- Insomnia**
in women, 258-259
- Interferon(s)**
BOOP due to, 88
for pulmonary fibrosis, 763-764
lung diseases due to, 58-59
- Interleukin-2**
lung diseases due to, 59
pleural disease due to, 145
pulmonary edema due to, 93
- Interstitial lung disease, 409-419**
BAL in, 637-648
 - abnormal cellular profiles with, 641-643
 - applications of, 643-646
 - bronchoalveolar fluid processing in, 639-640
 - cellular components in
 - analysis of, 640
 - clinical use of, 638-640

- general considerations with, 641
 - technique of, 638-639
 - collagen vascular disease with
 - lung transplantation for, 776-777
 - demographics of, 411
 - described, 409-410
 - diagnosis of
 - chest radiography in, 414-415
 - CT in
 - high-resolution, 415-416, 457-458
 - invasive procedures in, 637-638
 - laboratory tests in, 414
 - physical examination in, 412-414
 - plain radiography in, 455-457
 - pulmonary function testing in, 416-419
 - pulmonary function tests in, 437-438
 - radiographic imaging in, 637-638
 - differential diagnosis of
 - pulmonary function tests in, 438-439
 - environment/occupation/medication history in, 412
 - exposures to, 412
 - familial
 - reduced surfactant protein C expression
 - associated with, 427-428
 - surfactant protein C mutations and, 427-428
 - family medical history and, 411
 - fibrosis-related, 668-677
 - imaging in, **455-465**
 - imaging of, **651-656**. See also specific disorders, e.g., *Desquamative interstitial pneumonitis*.
 - in patient with connective tissue disease, **549-559**
 - cryptogenic organizing pneumonia, 556
 - diagnosis of
 - laboratory screening in, 550-551
 - physical examination in, 549-550
 - mixed connective tissue disease, 555-556
 - polymyositis/dermatomyositis, 554-555
 - pulmonary hypertension, 554
 - rheumatoid arthritis
 - treatment of, 553
 - Sjögren's syndrome, 555
 - SLE, 530
 - systemic sclerosis, 553-554
 - undifferentiated connective tissue disease, 556
- inherited, **421-433**
 - described, 421-422
 - future directions in, 430
 - genetics of, 425-429
- lung transplantation for, **773-782**
 - coronary artery disease and, 778-779
 - indications for, 775-777
 - outcome after, 777-778
 - recipient selection for, 773-774
 - secondary pulmonary hypertension and, 779
 - special considerations for, 778-779
 - steroid-induced osteoporosis and, 779
 - surgical options in, 774-775
 - venous thromboembolism and, 779
- management of
 - response to
 - pulmonary function tests in, 443-446
- occupational, **467-478**. See also *Occupational interstitial lung disease*.
- onset of
 - history of, 410-411
- pathology of, **657-703**
 - acute diffuse alveolar hemorrhage, 666-668
 - acute fibrinous and organizing pneumonia, 665-666
 - airspace filling in, 682-686
 - analgesics, 663
 - ARDS and diffuse alveolar damage, 662
 - chemotherapeutic agents, 663
 - cigarette smoking-related, 695-698
 - collagen vascular diseases, 664-665
 - dermatomyositis/polymyositis
 - acute lung injury and, 665
 - drug reactions, 663, 680-681
 - eosinophilic lung disease, 663-664
 - fibrosis-related, 668-677
 - Hermansky-Pudlak syndrome, 670-672
 - infections, 663
 - interstitial mononuclear cells in, 677-682
 - lymphoid interstitial pneumonia, 681-682
 - nodules in, 686-690
 - nonspecific interstitial pneumonia, 672-675
 - radiation pneumonitis, 663
 - radiation reactions, 663
 - rheumatoid arthritis, 665
 - SLE, 665
- prognosis of
 - pulmonary function tests in, 439
- respiratory bronchiolitis-associated, **717-726**
 - clinical features of, 722-723
 - clinical issues with, 723
 - defined, 717-726
 - diagnostic evaluation of, 720-722
 - histopathology of, 718-719
 - imaging of, 654
 - prognosis of, 723
 - smoking and, 719-720
 - treatment of, 722-723
- resting and exercise physiology in, **435-437**
 - clinical applications of, 437-446
 - idiopathic pulmonary fibrosis, 439-441
 - Langerhans' cell histiocytosis, 443

- progressive systemic sclerosis, 441-442
 - sarcoidosis, 442-443
 - resting physiology in
 - gas exchange in, 435-437
 - lung volumes in, 435
 - rheumatoid, 552
 - rheumatoid arthritis-associated, 462-463
 - severity of
 - pulmonary function tests in, 439
 - SLE, 552
 - symptoms of
 - extrapulmonary, 411
 - respiratory, 411
 - systemic complaints in, 549
- Interstitial mononuclear cells
- in interstitial lung disease, 677-682
- Interstitial pneumonia
- acute. See *Acute interstitial pneumonia (AIP)*.
 - defined, 705
 - desquamative
 - lung transplantation for, 777
 - lymphoid
 - interstitial mononuclear cells in, 681-682
 - nonspecific, **705-715**. See also *Nonspecific interstitial pneumonia (NSIP)*.
 - drug-induced, 15
 - usual
 - pulmonary fibrosis in, 675-677
- Interstitial pneumonitis
- acute
 - imaging of, 654-655
 - desquamative
 - imaging of, 653-654
 - lymphoid, 655
 - nonspecific
 - imaging of, 651-653
 - usual
 - drug-induced, 15
 - imaging of, 651
- Intravenous immunoglobulin (IVIG)
- pleural disease due to, 147
- IPF. See *Idiopathic pulmonary fibrosis (IPF)*.
- Irinotecan, 58
- Isotretinoin
- pleural fluid eosinophilia due to, 143
- Itraconazole
- pleural disease due to, 146
- IVIG. See *Intravenous immunoglobulin (IVIG)*.

L

- Langerhans' cell histiocytosis, 462
- pulmonary, **561-571**. See also *Pulmonary Langerhans' cell histiocytosis (PLCH)*.
 - lung transplantation for, 777
 - resting and exercise physiology in, 443
- Leiomyoma(s)
- benign metastasizing. See *Benign metastasizing leiomyoma (BML)*.
 - uterine
 - metastatic
 - pathogenesis of, 343-344
- Leiomyosarcoma(s)
- uterine
 - metastatic low-grade
 - pathogenesis of, 344-345
- Leukotriene antagonists
- diffuse alveolar hemorrhage due to, 134
- Lipid abnormalities
- surfactant protein and
 - quantification of, 596-597
- Lung(s)
- farmer's, 532
 - fenfluramine in
 - accumulation of, 123
- Lung biopsy
- in PLCH, 566-567
 - surgical
 - in idiopathic pulmonary fibrosis, 628-630
 - pattern analysis approach to, 657-660
- Lung cancer
- gender and, **391-400**
 - biologic differences, 395-397
 - epidemiological differences, 393-394
 - genetic differences, 397-398
 - histologic distribution of, 398
 - hormonal differences, 397
 - in women
 - histologic distribution of, 398
 - incidence of, 391
 - mortality of, 391-392
 - occupational
 - in female workers, 275-276
 - radiation therapy for
 - lung damage after
 - manifestations of, 168-170
 - risk factors for, 392-398
 - smoking, 392-393

- therapy-induced
 - studies of, 217-219
- treatment of
 - gender effects on
 - outcomes of, 398
- Lung development
 - childhood, 239-240
 - fetal, 237-239
 - gender differences in
 - clinical implications of, 242-243
 - clinical significance of, 237-245
 - in adults, 241
 - smoking effects on, 241-242
 - perinatal, 237-239
 - pubertal, 239-240
 - smoking effects on
 - fetal, perinatal, and childhood, 240-241
- Lung diseases
 - chemotherapy-induced, 51-62
 - alkylating agents, 54-55
 - antimetabolites, 55-57
 - azathioprine, 55-56
 - bleomycin, 53-54
 - busulfan, 54
 - chlorambucil, 55
 - cyclophosphamide, 54-55
 - cytosine arabinoside, 56
 - fludarabine, 56
 - GCSF, 59
 - gemcitabine, 56
 - GM-CSF, 59
 - immune modulatory agents, 58-59
 - interferons, 58-59
 - interleukin-2, 59
 - melphalan, 55
 - methotrexate, 55
 - mitomycin C, 54
 - nitrosamines, 56-57
 - podophyllotoxins, 58
 - procarbazine, 59
 - tumor necrosis factor- α , 59
 - vinblastine, 60
 - zinostatin, 59
 - drug-induced, 15-19
 - BAL in, 25-34
 - as clinical diagnostic tool, 26-28
 - interpretation of, 26-27
 - described, 25
 - in differential diagnosis, 27-28
 - in disease activity assessment, 28
 - in drug-induced pneumonitis, 28-31
 - laboratory processing in, 26
 - procedure for, 25-26
 - technical aspects of, 25-26
 - BOOP due to, 16
 - chronic interstitial pneumonia due to, 38-39
 - diagnosis of
 - criteria for, 37-38
 - methods in, 36-37
 - diagnostic features of, 28-29
 - diffuse alveolar damage due to, 39
 - granulomatous inflammation due to, 41-42
 - hypersensitivity lung disease due to, 16
 - lung injury patterns in, 38-42
 - nonspecific interstitial pneumonia due to, 15
 - organizing pneumonia due to, 39-40
 - pathologic characteristics of, 35-43
 - clinical scenarios relevant to, 35-36
 - pleural disease due to, 42
 - pulmonary edema due to, 40
 - pulmonary edema with/without diffuse
 - alveolar damage due to, 17-18
 - pulmonary eosinophilia due to, 40
 - pulmonary hemorrhage due to, 18-19, 40-41
 - pulmonary hypertension due to, 41
 - pulmonary veno-occlusive disease due to, 41
 - usual interstitial pneumonitis due to, 15
 - vascular thrombosis due to, 41
 - vasculitis due to, 41
 - eosinophilic. See also *Eosinophilic lung disease*, *drug-induced*.
 - drug-induced, 73-84
 - infiltrative
 - noncytotoxic agents and, 45-50
 - aspirin, 46-47
 - gold salts, 48
 - hydrochlorothiazide, 48-49
 - methotrexate, 45-46
 - NSAIDs, 47
 - opioids, 49
 - D-penicillamine, 47-48
 - interstitial, 409-419. See also *Interstitial lung disease*.
 - radiation-induced, 20-21
 - rheumatoid-associated
 - treatment of, 553
 - transplant-related, 19-20
 - graft *versus* host disease, 20
 - infections, 19-20
 - posttransplant lymphoproliferative disorder, 20
- Lung injuries
 - acute
 - pattern of, 660-668
 - iatrogenic embolization, 22
 - transbronchial-induced, 22-23
 - transfusion-related, 22

- Lung macrophages
phenotypic and functional studies of, 599
- Lung transplantation. See also specific indications, e.g., *Sarcoidosis*, *lung transplantation for*.
for interstitial lung disease, 773-782. See also *Interstitial lung disease*, *lung transplantation for*.
- Lupus erythematosus
drug-induced, 514-515
- Lupus pleuritis
drug-induced, 147-148
- Lymphangioliomyomatosis (LAM), 461-462, 573-582
age as factor in, 355
BML and, 354-355
described, 355-356, 573
diagnosis of
pulmonary function tests in, 574
hormonal features of, 357-358, 578-579
lung transplantation for, 776
pathology of, 574
pulmonary fibrosis-related, 422-423
radiographic features of, 573-574
treatment of, 357
approaches to, 579-580
tuberous sclerosis complex and, 356-357, 575-578
- Lymphangitic carcinomatosis
nodules in, 690
uterine and cervical cancer and, 386-387
- Lymphangitis
pulmonary
breast cancer and, 384
- Lymphatic carcinomatosis, 381
- Lymphocyte immune globulin
ARDS due to, 98
- Lymphoid interstitial pneumonia
interstitial mononuclear cells in, 681-682
- Lymphoid interstitial pneumonitis, 655

M

- Macrophage(s)
airspace filling and, 684-685
lung
phenotypic and functional studies of, 597-599
- Malignancy(ies)
nonpulmonary
in women
prognostic factors related to, 387-388
survival factors related to, 387-388
thoracic manifestations of, 379-390.
See also specific types, e.g., *Breast cancer*.
- Marijuana
pulmonary effects of, 205-207
- Melphalan
lung diseases due to, 55
- Men
sleep patterns of, 258
- Mendelian disorders
pulmonary fibrosis and, 422-425
- Menopause
sleep effects of, 260
- Mesalamine
pleural disease due to, 146
- Mesothelioma(s)
pleural
malignant
therapy-induced, 220
- Metabolic diseases
pulmonary fibrosis-related, 424-425
- Metabolic idiosyncrasy
drug-induced lung cell injury due to, 8-9
- Metal(s)
occupational interstitial lung disease due to, 473-475
- Metastasis
biology of, 379-380
pulmonary
patterns of, 380-382
- Metastatic low-grade uterine leiomyosarcoma
pathogenesis of, 344-345
- Metastatic uterine leiomyoma
pathogenesis of, 343-344
- Methadone
pulmonary edema due to, 96
- Methotrexate
for polymyositis/dermatomyositis, 555
in interstitial lung disease, 680
infiltrative lung diseases due to, 45-46
lung diseases due to, 55

- pleural disease due to, 142
- pulmonary edema due to, 93
- pulmonary infection due to, 180
- Methysergide
 - pleural disease due to, 141
- Microolithiasis
 - alveolar
 - pulmonary, 429
- Microscopic polyangiitis
 - diffuse alveolar hemorrhage due to, 587-588
- Minocycline
 - BOOP due to, 85
- Minoxidil
 - pleural disease due to, 139-140
- Mitomycin
 - diffuse alveolar hemorrhage due to, 133-134
 - pleural disease due to, 142
 - pulmonary edema due to, 93
- Mitomycin C
 - lung diseases due to, 54
- Mixed connective tissue disease, 555-556
 - pulmonary fibrosis in, 669-670
- Mode of onset
 - as factor in NSIP, 709
- Mononuclear cells
 - interstitial
 - in interstitial lung disease, 677-682
- Morphine
 - pulmonary edema due to, 96
- Muromonab-CD3
 - pulmonary edema due to, 93
- Mycobacterial infection
 - atypical
 - bioaerosol-associated
 - interstitial mononuclear cells in, 679
 - noncystic fibrosis bronchiectasis and, 364-365
- Mycobacterial-induced hypersensitivity pneumonitis, 532-533
- Mycobacterium tuberculosis*
 - disorders due to
 - corticosteroids and, 179-180
- Myofibroblast(s)
 - recruitment and maintenance of
 - in idiopathic pulmonary fibrosis, 754
- N**

- "Narcotic lung," 201
- Neoplastic cells
 - nodules in, 690
- Neurofibromatosis
 - pulmonary fibrosis-related, 423-424
- Neuromuscular junction
 - in neuromuscular respiratory system
 - dysfunction, 158
- Neuromuscular respiratory system
 - dysfunction of
 - clinical impact of, 153-154
 - iatrogenic-induced, 153-164
 - anesthetics in, 155
 - corticosteroids, 159
 - described, 154-161
 - direct lesions, 160
 - drug-related ventilatory
 - depression, 155
 - dyskinesia, 156
 - hiccups, 156
 - indirect mechanisms in, 160
 - neuromuscular junction in, 158
 - nonsurgical procedures, 156
 - respiratory muscle atrophy, 160
 - surgical procedures, 155-156
- Neuropsychiatric agents
 - pulmonary edema due to, 95
- Neutrophil(s)
 - airspace filling and, 682
- Nifedipine
 - pulmonary edema due to, 94
- Nitric oxide
 - pulmonary edema due to, 94
- Nitrofurantoin
 - acute lung injury and, 663
 - ARDS due to, 98
 - BOOP due to, 85-86
 - pleural fluid eosinophilia due to, 143-144
- Nitrosamine(s)
 - lung diseases due to, 56-57
- Nodule(s)
 - in interstitial lung disease, 686-690
 - parenchymal, 381
- Noncystic fibrosis bronchiectasis
 - mycobacterial infection and, 364-365

Noncytotoxic agents

infiltrative lung diseases due to, **45-50**. See also *Lung diseases, infiltrative, noncytotoxic agents and*.

Nonfibrous dust

occupational interstitial lung disease due to, 472-473

Nonspecific interstitial pneumonia (NSIP),

705-715

diagnostic considerations in, 706-708

differential diagnosis of, 708

drug-induced, 15

histologic variability in, 706

idiopathic

described, 705-706

interstitial mononuclear cells in, 679

prognostic factors in, 709-712

age, 709

clubbing, 709

diagnostic tests, 709

etiology, 711-712

gender, 709

mode of onset, 709

smoking, 709

treatment, 710-711

pulmonary fibrosis in, 672-675

surgical lung biopsy in, 706

treatment of, 712

NSAIDs. See *Anti-inflammatory drugs, nonsteroidal (NSAIDs)*.

NSIP. See *Nonspecific interstitial pneumonia (NSIP)*.

O

Obesity

in women

bronchial hyperresponsiveness and, 323

Obesity hypoventilation syndrome, 264

Obstetric agents

pulmonary edema due to, 96-97

Obstructive sleep apnea

snoring and, 261-262

treatment of, 262-263

CPAP in, 263

oral appliances in, 263

surgical, 263

weight loss in, 262-263

Occupational asthma

in female workers, 276

Occupational interstitial lung disease, **467-478**

causes of

fibrous dust, 470-472

metals, 473-475

nonfibrous dust, 472-473

described, 467

emerging, 475

epidemiology of, 467-468

evaluation of, 468-469

management of, 470

pathogenesis of, 469-470

Occupational lung cancer

in female workers, 275-276

Occupational lung disease

gender and, 269-273

in female workers, 273-277

asbestosis, 274-275

occupational asthma, 276

signs and symptoms of, 276-277

silicosis, 273-274

research methodology in, 269-273

sex and, 269-270

women and, **269-279**

Open lung biopsy

for pulmonary complications of bone marrow transplantation, 195

Opiate(s)

infiltrative lung diseases due to, 49

Oral appliances

for obstructive sleep apnea, 263

Oral contraceptives

venous thromboembolism due to, 283-285

Organizing pneumonia

acute lung injury and, 665-666

airspace filling and, 682-684

bronchiolitis obliterans

drug-induced infiltrative lung disease and, 551-554

drug-induced infiltrative lung disease and, 551-554

drug-induced lung disease and, 39-40

Osteoporosis

steroid-induced

lung transplantation for interstitial lung disease and, 779

Ovarian cancer

endobronchial disease due to, 385

parenchymal disease due to, 385

pleural disease due to, 385

- prevalence of, 384
 - stage IV
 - described, 385
 - thoracic manifestations of, 384-385
- Oxytocin
- pulmonary edema due to, 96
- P**
-
- Paclitaxel
- lung diseases due to, 58
- Panbronchiolitis
- diffuse
 - nodules in, 689-690
- Parenchymal disease
- cervical cancer and, 386
 - ovarian cancer and, 385
 - uterine cancer and, 386
- Parenchymal nodules, 381
- D-Penicillamine
- infiltrative lung diseases due to, 47-48
 - pleural disease due to, 145
- Pentostatin
- pulmonary edema due to, 93
- Perinatal period
- lung development in, 237-239
 - smoking effects on, 240-241
- Peripartum cardiomyopathy, 303
- Phenothiazine(s)
- pulmonary edema due to, 95
- Phenylephrine
- pulmonary edema due to, 94
- Phenytoin
- BOOP due to, 88
- Pirfenidone
- for pulmonary fibrosis, 764
- Plain radiography
- in interstitial lung disease, 455-457
- PLCH. See *Pulmonary Langerhans' cell histiocytosis (PLCH)*.
- Pleural disease, 382
- cervical cancer and, 386, 387
 - drug-induced, 139-151
 - acyclovir, 144
 - amiodarone, 140
 - bleomycin, 141
 - α -blockers, 140
 - bromocriptine, 141
 - cardiovascular agents, 139-140
 - chemotherapeutic agents, 141-143
 - clozapine, 144-145
 - cyclophosphamide, 142-143
 - ergoline drugs, 141
 - GCSF, 145
 - interleukin-2, 145
 - itraconazole, 146
 - IVIG, 147
 - mesalamine, 146
 - methotrexate, 142
 - methysergide, 141
 - minoxidil, 139-140
 - mitomycin, 142
 - D-penicillamine, 145
 - pleural fluid eosinophilia in, 143-144
 - procabazine, 141-142
 - sclerotherapeutic agents, 140-141
 - simvastatin, 146
 - trogilazone, 146-147
 - L-tryptophan, 146
 - drug-induced lung disease and, 42
 - ovarian cancer and, 385
 - uterine cancer and, 386, 387
- Pleural effusion
- amiodarone and, 68-69
 - breast cancer and, 383-384
- Pleural fluid eosinophilia
- drug(s) causing, 143-144
 - drug-induced pleural disease and, 143-144
- Pleural mesothelioma
- malignant
 - therapy-induced, 220
- Pleural thickening
- amiodarone and, 69
- Pleuritis
- lupus
 - drug-induced, 147-148
- Pneumocystis carinii* pneumonia
- after bone marrow transplantation, 192
 - corticosteroids and, 178-179
- Pneumonia(s)
- cryptogenic organizing. See *Cryptogenic organizing pneumonia (COP)*.
 - after bone marrow transplantation, 194
 - eosinophilic
 - airspace filling in, 684-685

- interstitial. See *Interstitial pneumonia*.
- chronic
 - drug-induced lung disease and, 38-39
 - nonspecific
 - drug-induced, 15
- organizing
 - acute lung injury and, 665-666
 - airspace filling and, 682-684
 - bronchiolitis obliterans
 - drug-induced infiltrative lung disease and, 509-512
 - bronchiolitis obliterans with
 - drug-induced, 16
 - cryptogenic, 556
 - drug-induced infiltrative lung disease and, 509-512
 - drug-induced lung disease and, 39-40
- Pneumocystis carinii*
 - after bone marrow transplantation, 192
 - corticosteroids and, 178-179
 - pregnancy and, 306-307
- Pneumonitis
 - aspiration
 - pregnancy and, 306
 - classic
 - radiation therapy and, 165-166
 - CMV
 - after bone marrow transplantation, 191-192
 - desquamative interstitial
 - imaging of, 653-654
 - drug-induced
 - BAL in, 28-31
 - herpes simplex
 - after bone marrow transplantation, 191
 - hypersensitivity, 531-547. See also *Hypersensitivity pneumonitis*.
 - interstitial mononuclear cells in, 677-679
 - interstitial. See *Interstitial pneumonitis*.
 - usual
 - drug-induced, 15
 - radiation
 - acute lung injury and, 663
 - SLE, 551
 - sporadic
 - radiation therapy and, 166-167
- Podophyllotoxin(s)
 - lung diseases due to, 58
- Polyangiitis
 - microscopic
 - diffuse alveolar hemorrhage due to, 587-588
- Polymyositis/dermatomyositis, 554-555
- Posttransplant lymphoproliferative disorder
 - transplant-related, 20
- PPH. See *Primary pulmonary hypertension (PPH)*.
- Preeclampsia
 - pregnancy and, 302-303
- Pregnancy
 - anatomic and physiologic changes during
 - respiratory function effects of, 299-300
 - pulmonary complications of, 299-310
 - air embolism, 304-305
 - amniotic fluid embolism, 301-302
 - amniotic fluid embolism and, 301-302
 - ARDS, 305
 - aspiration pneumonitis, 306
 - asthma, 307-308
 - HIV-related, 307
 - peripartum cardiomyopathy and, 303
 - pneumonia, 306-307
 - preeclampsia, 302-303
 - pulmonary edema, 303
 - respiratory failure, 300-301
 - thromboembolic disease, 303-304
 - tocolytic-induced pulmonary edema, 302
 - respiratory failure during, 300-301
 - sleep during, 259
 - sleep-disordered breathing and, 262
 - venous thromboembolism during, 288-293
 - clinical presentation of, 288-290
 - diagnosis of, 288-290
 - thrombophilia and, 290-293
 - treatment of, 290
- Primary pulmonary hypertension (PPH)
 - anorectic pulmonary hypertension and
 - comparison of, 121-122
 - defined, 120-121
 - described, 120-121
 - epidemiology of, 373-374
 - gender issues in, 373-374
 - genetics of, 374
 - overview of, 373
 - pathogenetic mechanisms in, 374
 - pathophysiology of, 121
 - prevalence of, 373
 - serotonin and, 122-123
- Procainamide
 - lupus pleuritis due to, 148
- Procarbazine
 - lung diseases due to, 59
 - pleural disease due to, 141-142
- Profibrotic Th2 cytokines
 - in idiopathic pulmonary fibrosis, 753

- Progressive systemic sclerosis
 CREST syndrome and, 463
 pulmonary fibrosis in, 669
 resting and exercise physiology in, 441-442
- Proliferation
 in idiopathic pulmonary fibrosis, 751-752
- Propoxyphene
 pulmonary edema due to, 96
- Propranolol
 pulmonary edema due to, 94
- Propylthiouracil
 diffuse alveolar hemorrhage due to, 132-133
 pleural fluid eosinophilia due to, 143
- Protamine
 pulmonary edema due to, 97
- Protein(s)
 surfactant
 lipid abnormalities and
 quantification of, 596-597
- Proteinaceous material
 airspace filling in, 685-686
- Proteinosis
 pulmonary alveolar, **593-613**. See also
 Pulmonary alveolar proteinosis.
- Pseudomonas aeruginosa* infection
 cystic fibrosis and
 sex-related effects of, 367-368
- Puberty
 lung development in, 239-240
- Pulmonary alveolar microlithiasis, 429
- Pulmonary alveolar proteinosis, 464, **593-613**
 airspace filling in, 685-686
 clinical features of, 593-594
 congenital
 mutation of CSF2RB gene and, 426-427
 described, 593
 differential diagnosis of, 594-595
 evaluation of
 algorithm for, 595
 clinical examination in, 594
 laboratory markers in, 594
 medical history of, 593-594
 pulmonary function tests in, 594
 radiology in, 594
 therapeutic lung lavage in, 595
 GM-CSF for, 596, 605-606
 outcome of, 595-596
- Pulmonary arteries
 iatrogenic embolization to, 22
- Pulmonary capillaritis
 isolated
 diffuse alveolar hemorrhage due to, 589
- Pulmonary complications
 in bone marrow transplantation, **187-199**.
 See also *Bone marrow transplantation*,
 pulmonary complications in.
- Pulmonary edema
 after bone marrow transplantation, 189
 drug-induced, **91-97**
 acetazolamide, 94
 amlodipine, 93-94
 analgesic agents, 95-96
 antineoplastic agents, 92-93
 aspirin, 95-96
 calcium channel blockers, 93-94
 cardiovascular agents, 93-94
 chlorothiazide/hydrochlorothiazide,
 94-95
 cocaine, 97
 contrast agents, 97
 cytarabine arabinoside, 92-93
 epinephrine, 94
 epoprostenol, 94
 ergonovine, 96
 ethchlorvynol, 95
 gemcitabine, 93
 heroin, 97
 immunosuppressant agents, 92-93
 interleukin-2, 93
 methadone, 96
 methotrexate, 93
 mitomycin, 93
 morphine, 96
 muromonab-CD3, 93
 neuropsychiatric agents, 95
 nifedipine, 94
 nitric oxide, 94
 obstetric agents, 96-97
 oxytocin, 96
 pentostatin, 93
 phenothiazines, 95
 phenylephrine, 94
 propoxyphene, 96
 propranolol, 94
 protamine, 97
 renal agents, 94-95
 respiratory agents, 94
 tocolytic agents, 96-97
 tretinoin, 93

- tricyclic antidepressants, 95
- verapamil, 94
- drug-induced lung disease and, 40
- pregnancy and, 303
- tocolytic-induced
 - pregnancy and, 302
- with/without diffuse alveolar damage
 - drug-induced, 17-18
- Pulmonary embolism
 - deep venous thrombosis and
 - relationship between, 281
- Pulmonary eosinophilia
 - drug-induced lung disease and, 40
- Pulmonary fibrosis
 - drug reactions in, 670
 - familial hypocalciuric hypercalcemia and, 424
 - Hermansky-Pudlak syndrome and, 424
 - idiopathic, **621-634**. See also *Idiopathic pulmonary fibrosis*.
 - familial, 428-429
 - genetic polymorphisms and
 - relationship between, 429-430
 - resting and exercise physiology in, 439-441
 - in systemic connective tissue diseases, 668-670
 - lymphangioleiomyomatosis and, 422-423
 - mendelian disorders associated with, 422-425
 - metabolic diseases and, 424-425
 - neurofibromatosis and, 423-424
 - radiation therapy and, 167-168
 - treatment of
 - immunosuppressive
 - traditional
 - limitations of, 762-763
 - medical, **759-772**
 - antioxidants in, 764-765
 - baseline demographic variables in, 761
 - dynamic clinical variables in, 761-762
 - eicosanoids in, 766
 - endothelin in, 765
 - interferons in, 763-764
 - outcome predictors of, 761-762
 - pirfenidone in, 764
 - renin-angiotensin-aldosterone system in, 766
 - response to
 - definitions of, 761-762
 - statins in, 767
 - TGF- α in
 - antagonism of, 763
 - TNF- α in, 765
 - type 1/type 2 cytokine imbalance in, 765-766
- novel agents in
 - rationale for, 763
- tuberosclerosis and, 422-423
- untreated
 - natural history of, 759-761
- Pulmonary function tests
 - for amiodarone pulmonary toxicity, 66-67
 - for pulmonary complications of bone marrow transplantation, 195
 - in COP, 732
 - in idiopathic pulmonary fibrosis, 626
 - in interstitial lung disease diagnosis, 416-419, 437-438
 - in interstitial lung disease differential diagnosis, 438-439
 - in interstitial lung disease management response, 443-446
 - in interstitial lung disease prognosis, 439
 - in interstitial lung disease severity, 439
 - in lung damage assessment after radiation therapy for lung cancer, 169
 - in lymphangioleiomyomatosis, 574
 - in respiratory bronchiolitis-associated desquamative interstitial pneumonia, 720-722
 - in respiratory bronchiolitis-associated interstitial lung disease, 720-722
- Pulmonary hemorrhage
 - drug-induced, 18-19
 - drug-induced lung disease and, 40-41
- Pulmonary hypertension, 554
 - anorectic
 - PPH and
 - comparison of, 121-122
 - appetite suppressant-induced
 - history of, 119-120
 - drug therapy and, **119-127**
 - cocaine, 123-124
 - dexfenfluramine, 122
 - eosinophilic myalgia syndrome, 124
 - fenfluramine, 122
 - Spanish oil syndrome, 124
 - drug-induced lung disease and, 41
 - idiopathic. See *Primary pulmonary hypertension (PPH)*.
 - in bush tea drinkers, 124
 - primary. See *Primary pulmonary hypertension (PPH)*.
 - secondary
 - lung transplantation for interstitial lung disease and, 779

Pulmonary infection**drug-induced, 177-185**

alemtuzumab in, 182

Aspergillus spp. disorders, 179

corticosteroids in, 177-180

cyclosporin in, 180

described, 177

methotrexate in, 180

Mycobacterium tuberculosis disorders,
179-180*Pneumocystis carinii* pneumonia,
178-179

purine analogs in, 181-182

rituximab in, 182-183

tacrolimus in, 180

tumor necrosis factor- α antagonists in,
180-181**Pulmonary Langerhans' cell histiocytosis (PLCH),****561-571**

bronchoscopy in, 566-567

clinical features of, 564-565

described, 561

diagnostic algorithm in, 567

epidemiology of, 561-562

long-term outcomes of, 568-569

lung biopsy in, 566-567

lung transplantation for, 777

management of, 567-568

pathogenesis of, 562-563

pathologic findings in, 563-564

prognosis of, 568-569

radiologic features of, 565-566

Pulmonary lobule**secondary**

anatomy of, 458

Pulmonary lymphangitis

breast cancer and, 384

Pulmonary metastasis

patterns of, 380-382

Pulmonary sarcoidosis, 521-530. See also*Sarcoidosis, pulmonary.***Pulmonary system**pregnancy effects on, 299-310. See also
*Pregnancy, pulmonary complications of.***Pulmonary toxicity**

amiodarone-induced, 63-72. See also

Amiodarone, pulmonary toxicity
associated with.

categories of, 1

mechanisms in, 1-14

Pulmonary vascular diseasegender issues in, 373-377. See also specific
disorders, e.g., *Primary*
pulmonary hypertension.
autoimmune diseases, 375-376
scleroderma, 375-376**Pulmonary veno-occlusive disease**

drug-induced lung disease and, 41

Purine analogs

pulmonary infection due to, 181-182

Q**Quinidine**

lupus pleuritis due to, 148

R**Radiation****reactions to**

acute lung injury and, 663

Radiation carcinogenesis

thoracic malignancies, 216-217

Radiation pneumonitis

acute lung injury and, 663

Radiation syndromes

mechanistic studies of, 165-168

Radiation therapy**for lung cancer**

early stage, 169-170

lung damage after

assessment of

dyspnea score in, 168-169

lung function tests in, 169

manifestations of, 168-170

patient mortality related to, 169

for lung malignancies other than
cancer, 170

lung diseases due to, 20-21

lung toxicity due to

factors predicting, 171-172

pneumonitis due to

classic, 165-166

sporadic, 166-167

pulmonary complications of,
165-175

management of, 172

prevention of, 172

pulmonary fibrosis due to, 167-168

thoracic malignancies due to, 216-217

- Radiography**
chest. See *Chest radiography*.
in idiopathic pulmonary fibrosis, 626-628
plain
in interstitial lung disease, 455-457
- Radiology**
for pulmonary complications of bone marrow transplantation, 194
in respiratory bronchiolitis-associated desquamative interstitial pneumonia, 720-722
in respiratory bronchiolitis-associated interstitial lung disease, 720-722
- Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF)**
ARDS due to, 98
- Renal agents**
pulmonary edema due to, 94-95
- Renin-angiotensin-aldosterone system**
in pulmonary fibrosis, 766
- Reproductive hormones**
female, 247-248
- Respiratory agents**
pulmonary edema due to, 94
- Respiratory bronchiolitis**
defined, 717
desquamative interstitial pneumonia and, 717-726
interstitial lung disease and, 717-726
- Respiratory bronchiolitis-associated interstitial lung disease**
imaging of, 654
- Respiratory diseases**
iatrogenic
chest imaging in, 15-24
- Respiratory failure**
during pregnancy, 300-301
- Respiratory function**
anatomic and physiologic changes during pregnancy effects on, 299-300
- Respiratory muscle atrophy**
iatrogenic-induced, 160
- Respiratory system**
sleep and, 260-261
- Restless legs syndrome**
sleep effects of, 259-260
- Rheumatoid arthritis, 552-553**
acute lung injury and, 665
pulmonary fibrosis in, 668-669
- Rheumatoid arthritis-associated interstitial lung disease, 462-463**
- Rituximab**
pulmonary infection due to, 182-183
-
- S**
- Sarcoidosis, 458-459**
drug-induced, 513-514
lung transplantation for, 775-776
nodules in, 687-688
pulmonary, 521-530
clinical presentation of, 521-522
diagnosis of, 522-525
treatment of, 525-528
resting and exercise physiology in, 442-443
- Scleroderma**
gender issues in, 375-376
- Sclerosis(es)**
systemic, 553-554
tuberosus
pulmonary fibrosis-related, 422-423
- Sclerotherapeutic agents**
pleural disease due to, 140-141
- Secondary pulmonary hypertension ,**
lung transplantation for interstitial lung disease and, 779
- Selective estrogen receptor modulators (SERMs)**
venous thromboembolism due to, 287-288
- SERMs. See Selective estrogen receptor modulators (SERMs).**
- Serotonin**
PPH due to, 122-123
- Sex**
as factor in
cystic fibrosis and *Pseudomonas aeruginosa* infection, 367-368
as factor in bronchiectasis, 367-369
as factor in occupational lung disease, 269-270
defined, 269
- Silicosis, 460**
complicated, 460
in female workers, 273-274
simple, 460

- Simvastatin
pleural disease due to, 146
- Sjögren's syndrome, 555
pulmonary fibrosis in, 670
- SLE. See *Systemic lupus erythematosus (SLE)*.
- Sleep, 257-268
in women
conditions impacting, 258-260
during pregnancy, 259
insomnia effects on, 258-259
menopause effects on, 260
restless legs syndrome effects on, 259-260
vs. men, 258
overview of, 257-258
respiration during
drug effects on, 156
respiratory physiology in, 260-261
- Sleep apnea
obstructive. See *Obstructive sleep apnea*.
- Sleep patterns
women's vs. men's, 258
- Sleep-disordered breathing
pregnancy and, 262
- Smoking
as factor in NSIP, 709
as risk factor for lung cancer, 392-393
cigarette
hypersensitivity pneumonitis due to, 534
interstitial lung disease related to, 695-698
in women
bronchial hyperresponsiveness and, 323
lung development effects of
fetal, perinatal, and childhood, 240-241
in adults, 241-242
- Snoring
obstructive sleep apnea and, 261-262
- Sodium morrhuate/absolute alcohol
pleural disease due to, 140-141
- Spanish oil syndrome, 124
- Statin(s)
for pulmonary fibrosis, 767
- Steroid(s)
osteoporosis due to
lung transplantation for interstitial lung disease
and, 779
- Substrate metabolism
exercise performance in women effects of, 251
- Sulfasalazine
BOOP due to, 87-88
- Surfactant(s)
kinetic studies of, 597
metabolism of, 597
- Surfactant protein
lipid abnormalities and
quantification of, 596-597
- Surfactant protein C expression
reduced
familial interstitial lung disease and,
427-428
- Surfactant protein C mutations
familial interstitial lung disease and,
427-428
- Systemic lupus erythematosus (SLE), 551-552
acute lung injury and, 665
pulmonary fibrosis in, 669
- Systemic lupus erythematosus (SLE) interstitial lung
disease, 552
- Systemic lupus erythematosus (SLE)
pneumonitis, 551
- Systemic sclerosis, 553-554
-
- ## T
- Tacrolimus
pulmonary infection due to, 180
- TGF- α . See *Transforming growth factor- α (TGF- α)*.
- Thermoregulation
exercise performance in women effects of,
251-253
- Thoracic cancer
survival after, 215
therapy-induced, 215-224. See also *Thoracic malignancies, therapy-induced*.
- Thoracic endometriosis, 311-319. See also
Endometriosis, thoracic.
- Thoracic malignancies
causes of
previous radiation, 216
therapy-induced, 215-224
detection of, 215-216
diagnosis of, 215-216
esophageal cancer, 219
lung cancer, 217-219
pleural mesothelioma, 220

- Thoracoscopic lung biopsy
 in respiratory bronchiolitis-associated desquamative interstitial pneumonia, 722
 in respiratory bronchiolitis-associated interstitial lung disease, 722
- Thoracoscopy
 in thoracic endometriosis, 314
- Thromboembolic disease
 pregnancy and, 303-304
- Thromboembolism
 venous. *See Venous thromboembolism.*
- Thrombolytic agents
 diffuse alveolar hemorrhage due to, 134
- Thrombophilia
 pregnancy-related venous thromboembolism and, 290-293
- Thrombosis(es)
 vascular
 drug-induced lung disease and, 41
- Ticlopidine
 BOOP due to, 88
- TNF- α . *See Tumor necrosis factor- α (TNF- α).*
- Tobacco use
 in women
 bronchial hyperresponsiveness and, 323
- Tocolytic agents
 pulmonary edema due to, 96-97
- Tocolytic-induced pulmonary edema
 pregnancy and, 302
- TRALI. *See Transfusion-related acute lung injury (TRALI).*
- Transbronchial-induced lung injuries, 22-23
- Transforming growth factor- α (TGF- α)
 for pulmonary fibrosis
 antagonism of, 763
- Transfusion(s)
 lung injuries due to, 22
- Transfusion-related acute lung injury (TRALI)
 antibody-mediated model of, 103-104
 biologically-active mediator model of, 104-105
 causes of, 105
 clinical considerations in, 105
 clinical syndrome of, 101-102
 differential diagnosis of, 101-102
 future of, 106
 incidence of, 105-106
 pathophysiology of, 102-105
 pulmonary injury due to, 101-107
 described, 101
 recognition of, 106
 reporting of, 106
- Transplantation(s)
 bone marrow
 pulmonary complications in, 187-199.
 See also Bone marrow transplantation, pulmonary complications in.
 lung. *See Lung transplantation.*
 lung diseases related to, 19-20
- Tretinoin
 pulmonary edema due to, 93
- Troglitazone
 pleural disease due to, 146-147
- L-Tryptophan
 BOOP due to, 88-89
 pleural disease due to, 146
- Tuberous sclerosis
 pulmonary fibrosis-related, 422-423
- Tuberous sclerosis complex
 lymphangioleiomyomatosis and, 575-578
 lymphangioleiomyomatosis and, 356-357
- Tumor emboli
 breast cancer and, 384
- Tumor necrosis factor- α (TNF- α)
 for pulmonary fibrosis, 765
 lung diseases due to, 59
- Tumor necrosis factor- α antagonists
 pulmonary infection due to, 180-181
- Type 1/type 2 cytokine imbalance
 in pulmonary fibrosis, 765-766
-
- U**
- Undifferentiated connective tissue disease, 556
- Usual interstitial pneumonia
 pulmonary fibrosis in, 675-677
- Usual interstitial pneumonitis
 drug-induced, 15
- Uterine cancer
 endobronchial disease due to, 386-387
 lymphangitic carcinomatosis due to, 386-387
 parenchymal disease due to, 386
 pleural disease due to, 386, 387

- prevalence of, 386
- thoracic manifestations of, 385-387
- Uterine leiomyoma
 - metastatic
 - pathogenesis of, 343-344
- Uterine leiomyosarcoma
 - metastatic low-grade
 - pathogenesis of, 344-345

V

- Valproic acid
 - pleural fluid eosinophilia due to, 143
- Vascular disease
 - collagen, 462-463
- Vascular thrombosis
 - drug-induced lung disease and, 41
- Vasculitis
 - drug-induced lung disease and, 41
- Vasoreactivity
 - defined, 373
- Venous thromboembolism
 - epidemiology of, 281-283
 - gender issues and, **281-297**
 - hormonal therapy and, 283-288. See also *Hormonal therapy, venous thromboembolism due to.*
 - lung transplantation for interstitial lung disease and, 779
 - pregnancy and, 288-293. See also *Pregnancy, venous thromboembolism during.*
 - risk factors for, 281-283
- Ventilation
 - aerobic capacity effects of, 250-251
 - alveolar
 - neuromuscular determinants of, 153
- Verapamil
 - pulmonary edema due to, 94
- Vinblastine
 - lung diseases due to, 60

- Vinca alkaloids
 - ARDS due to, 98
 - bronchospasm due to, 113
- Viral infections
 - after bone marrow transplantation, 190-191
- Vocal cord dysfunction
 - in women, 324-328
 - causes of, 325-326
 - diagnosis of, 326-327
 - exertional dyspnea and, 325
 - management of, 327-328
 - prevalence of, 324-325

W

- Wegener's granulomatosis
 - diffuse alveolar hemorrhage due to, 587
- Weight loss
 - for obstructive sleep apnea, 262-263
- Women
 - body composition in, 248-249
 - body size of, 248-249
 - burden of work on, 273-277
 - cigarettes and, 332-333
 - COPD in
 - clinical course of, 338-339
 - epidemiology of, 333-335
 - exercise performance in
 - physiologic considerations in, **247-255.**
 - See also *Exercise performance, in women.*
 - lung cancer in. See also *Lung cancer, gender and.*
 - occupational lung disease in, **269-279.** See also *Occupational lung disease.*
 - reproductive hormones in, 247-248
 - sleep in. See *Sleep, in women.*
 - sleep patterns of, 258

Z

- Zinostatin
 - lung diseases due to, 59